Gene Circuit Therapeutics Market Report 2026

The gene circuit therapeutics market size has grown exponentially in recent years. It will grow from $1.84 billion in 2025 to $2.25 billion in 2026 at a compound annual growth rate (CAGR) of 22.3%. The growth in the historic period can be attributed to advances in synthetic biology research, early success of gene editing technologies, growing academic research funding, increased understanding of cellular signaling pathways, expansion of immuno-oncology research.

The gene circuit therapeutics market size is expected to see exponential growth in the next few years. It will grow to $5.03 billion in 2030 at a compound annual growth rate (CAGR) of 22.3%. The growth in the forecast period can be attributed to increasing clinical translation of gene circuit therapies, rising demand for highly targeted treatments, growing adoption of programmable cell therapies, expansion of rare disease gene therapy pipelines, increased investments in next-generation genetic medicines. Major trends in the forecast period include increasing development of programmable gene circuits, rising adoption of logic-gated cell therapies, growing integration of synthetic biology platforms, expansion of precision-controlled gene expression systems, enhanced focus on safety switch mechanisms.

The increasing demand for personalized medicine is expected to drive the growth of the gene circuit therapeutics market in the coming years. Personalized medicine involves customizing medical treatment according to the unique characteristics of each patient, often using genetic, biomarker, or molecular profiling. This rising demand is fueled by advancements in genomics and synthetic biology, as they allow for more precise disease targeting and improved treatment outcomes. Gene circuit therapeutics are essential in advancing personalized medicine by programming cells and microbes with logic systems that can sense, compute, and respond to specific disease conditions, enabling safer, more effective, and patient-specific therapies. For example, according to NHS England’s Genomics Statistical Commentary, a UK-based government authority, the total number of personalized genomic tests reached 65,884 in 2024, up 14% from 2023, indicating a growing demand for personalized medicine. As a result, the rising demand for personalized medicine is driving the expansion of the gene circuit therapeutics market.

Major companies in the gene circuit therapeutics market are concentrating on creating programmable gene circuits to achieve more accurate disease targeting, regulated therapeutic responses, and enhanced safety. Programmable circuits are engineered genetic networks composed of DNA, RNA, and regulatory proteins that perform logical operations within cells, allowing them to detect biological signals, process information, and produce specific outcomes. For example, in May 2023, Synlogic, Inc., a US-based clinical-stage biotechnology firm, shared new findings at the Synthetic Biology: Engineering, Evolution & Design (SEED) Conference regarding SYNB1353, a Synthetic Biotic drug candidate for homocystinuria (HCU). SYNB1353 uses genetically programmed probiotic bacteria with metabolic gene circuits designed to metabolize methionine and lower toxic homocysteine levels. This demonstrates how programmable circuits can be applied beyond oncology to rare metabolic diseases, emphasizing their potential to develop precise, long-lasting, and patient-friendly therapies.

In May 2025, AstraZeneca PLC, a UK-based pharmaceutical company, acquired EsoBiotec for an undisclosed sum. Through this acquisition, AstraZeneca intends to accelerate and expand its in vivo cell therapy capabilities, aiming to make innovative treatments for cancer and immune-mediated diseases more accessible and effective. EsoBiotec BV is a Belgium-based biotechnology company focused on developing gene circuit therapeutics.

Major companies operating in the gene circuit therapeutics market are GenScript Biotech, Agilent Technologies, Cellectis S.A., CRISPR Therapeutics, Beam Therapeutics, Twist Bioscience, Ginkgo Bioworks, Sangamo Therapeutics, Senti Biosciences, Editas Medicine, BlueRock Therapeutics, Synthego Corporation, Manus Bio, Strand Therapeutics, Dyno Therapeutics, Obsidian Therapeutics, Rubius Therapeutics, Precigen Inc., Aurealis Therapeutics, Synlogic Inc., Azalea Therapeutics.

North America was the largest region in the gene circuit therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene circuit therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gene circuit therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the gene circuit therapeutics market by increasing costs of imported gene synthesis tools, bioreactors, sequencing equipment, viral vectors, and advanced laboratory instruments. Biotechnology companies and research institutes in North America and Europe are most affected due to dependence on specialized imported equipment, while Asia-Pacific faces higher costs for manufacturing inputs. These tariffs are elevating development costs and slowing scale-up activities for early-stage therapies. However, they are also promoting domestic biomanufacturing investments, regional supply chain development, and innovation in cost-efficient genetic engineering platforms.

The gene circuit therapeutics market research report is one of a series of new reports that provides gene circuit therapeutics market statistics, including gene circuit therapeutics industry global market size, regional shares, competitors with a gene circuit therapeutics market share, detailed gene circuit therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the gene circuit therapeutics industry. This gene circuit therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gene circuit therapeutics is a form of medical treatment that employs engineered gene networks within cells to regulate their behavior. These gene circuits function like miniature biological programs, activating or deactivating genes in response to particular signals. Gene circuit therapeutics provide more precise disease treatment by allowing immune cells to target cancer or by safely controlling other cellular functions.

The primary product types in gene circuit therapeutics comprise synthetic gene circuits, programmable cell therapies, gene editing tools, and others. Synthetic gene circuits are designed networks of artificial genetic elements that interact to regulate gene expression, control cellular functions, and manage the production or modification of DNA and RNA for targeted therapies. Progress in this area is facilitating the creation of precise treatments for complex diseases. Major technologies in gene circuit therapeutics include CRISPR, TALEN, zinc finger nucleases, and others. These therapies are applied in fields such as oncology, rare diseases, infectious diseases, regenerative medicine, and more, and are used by pharmaceutical and biotechnology companies, academic and research institutions, hospitals, and clinics, among other organizations.

The gene circuit therapeutics market consists of revenues earned by entities by providing services such as cellular pathway modeling, gene circuit testing and validation, therapeutic gene delivery consulting, immune cell engineering support, and bioinformatics analysis for circuit optimization. The market value includes the value of related goods sold by the service provider or included within the service offering. The gene circuit therapeutics market includes sales of gene delivery vectors, inducible gene switches, synthetic promoters, engineered regulatory proteins, and cell-based assay kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.